Can Targeting the Restriction Point be a Therapeutic Strategy?
Yes, targeting the regulatory components of the restriction point has therapeutic potential. Inhibitors of CDKs (such as palbociclib) are already being used in the treatment of certain cancers. These inhibitors can restore control over the cell cycle, inducing cell cycle arrest and apoptosis in cancer cells.
